Method of analyzing hemoglobin and system for analyzing hemoglobin

The method and system for analyzing chromatograms in cation exchange liquid chromatography accurately detect abnormal hemoglobins like Hb-Riccarton, correcting HbA1c measurements by calculating slopes from chromatogram peaks and valleys, addressing the challenge of overlapping peaks and improving HbA1c measurement accuracy in diabetes diagnosis.

WO2024242127A1PCT designated stage expired Publication Date: 2024-11-28TOSOH CORP
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018778
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-24
Filing Date
2024-05-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Cation exchange liquid chromatography methods for measuring HbA1c struggle to accurately distinguish between HbE and Hb-Riccarton, leading to incorrect HbA1c measurement results due to overlapping peaks, with Hb-Riccarton often being misidentified as HbE, especially in samples containing abnormal hemoglobins.

Method used

A method and system that analyze chromatograms from blood samples using cation exchange liquid chromatography to detect peaks and valleys, calculating a slope between specific peaks to determine the presence of abnormal hemoglobins like Hb-Riccarton by comparing the slope to a reference threshold range, allowing for accurate HbA1c measurement by correcting for the presence of HbE or Hb-Riccarton.

Benefits of technology

Enables accurate reporting and correction of HbA1c measurement results by identifying abnormal hemoglobins, preventing underestimation and ensuring precise HbA1c estimation even in samples with Hb-Riccarton, thereby improving diagnostic accuracy in diabetes monitoring.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018778_28112024_PF_FP_ABST
    Figure JP2024018778_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a method for analyzing hemoglobin in a blood-derived sample, the method including: (1) a step for identifying a first peak with regard to HbA1c and a second peak with regard to HbA0; (2) a step for discerning whether there is furthermore a third peak present between the first peak and the second peak. The following steps are also implemented if it is discerned that the third peak is present and no other peak besides the third peak is present: (3) a step for calculating the slope of a straight line formed between a first valley present between the first peak and the third peak, and a second valley present between the second peak and the third peak; and (4) a step for estimating the presence of abnormal hemoglobin in the sample from a comparison of the slope and a predetermined reference threshold value range. Also provided is a system for implementing the method.
Need to check novelty before this filing date? Find Prior Art

Description

Method for analyzing hemoglobin and system for analyzing hemoglobin

[0001] The present invention relates to a method and a system for analyzing hemoglobin, specifically to a method and a system for measuring stable HbA1c in a blood sample by cation exchange liquid chromatography, which estimates an abnormal hemoglobin-containing sample and can report accurate measurement results.

[0002] Hemoglobin A1c (HbA1c, SA1c, or stable HbA1c) binds non-enzymatically to sugar (blood glucose) and its metabolites in the blood and is a biomarker widely used for diagnosing diabetes and monitoring its treatment.

[0003] A widely used method for measuring HbA1c is based on cation exchange liquid chromatography (CEX-HPLC). While the CEX-HPLC method for measuring HbA1c has the advantage of being able to detect hemoglobin fractions that arise due to mutations in the hemoglobin gene, known as abnormal hemoglobin, it also has the disadvantage that the presence of such fractions may impair the accuracy of the HbA1c results.

[0004] Hb-Riccarton is a type of abnormal hemoglobin that is widely found mainly in Europe. Non-Patent Document 1 reports that the results of HbA1c measurement using CEX-HPLC for samples containing Hb-Riccarton may be underestimated.

[0005] Furthermore, as shown in Patent Document 1, when a blood sample containing hemoglobin E (HbE), another type of abnormal hemoglobin, is measured by cation exchange chromatography, it is known that a peak due to HbE appears between stable HbA1c and HbA0.

[0006] As shown in Non-Patent Document 1, the peak derived from Hb-Riccarton appears at the same position as that of HbE, and therefore it has been difficult to distinguish between HbE and Hb-Riccarton in the measurement of HbA1c by cation exchange chromatography. Taking into account the case frequencies of HbE and Hb-Riccarton, the number of HbE cases is overwhelmingly greater, and there has been a high possibility that Hb-Riccarton will be reported as HbE.

[0007] JP 2012-215470 A

[0008] Brennan, Stephen O., et al. Hb Riccarton [α51 (CE9) Gly→ Ser]: a variant arising from a novel mutation in the α1 gene. Hemoglobin 29.1 (2005): 61-64.

[0009] In samples containing abnormal hemoglobin (e.g., Hb-Riccarton) other than HbE, which exhibits a peak between the HbA1c and HbA0 peaks, the HbA1c measurement results may be incorrect. The objective of this study is to develop a method or system that can estimate the presence of abnormal hemoglobin even when measuring such samples using cation exchange liquid chromatography.

[0010] As a result of intensive research into the above-mentioned problems, the inventors have found that the presence of abnormal hemoglobin can be estimated from a chromatogram of a sample containing multiple hemoglobins including HbA1c and HbA0, and have completed the present invention.

[0011] [1] A method for analyzing hemoglobin in a blood-derived sample, comprising the following steps: (1) identifying a first peak for HbA1c and a second peak for HbA0 from a chromatogram showing the elution of multiple hemoglobin fractions, including at least HbA1c and HbA0, obtained by subjecting the blood-derived sample to cation exchange liquid chromatography; (2) determining whether or not a third peak exists between the first and second peaks, and if it is determined that the third peak exists and that no peaks other than the third peak exist, the following steps are further carried out; (3) identifying a first valley existing between the first and third peaks and a second valley existing between the second and third peaks, and calculating the slope of a line formed between the first valley and the second valley; and (4) estimating the presence of abnormal hemoglobin in the sample by comparing the slope with a predetermined reference threshold range. [2] The method according to item 1, wherein in step (3), the slope is calculated from the minimum point of the first valley and the minimum point of the second valley. [3] The method according to item 1 or 2, wherein in step (4), if the slope deviates from the predetermined reference threshold range, it is estimated that an abnormal hemoglobin other than hemoglobin E is present in the sample. [4] The method according to item 3, wherein, when it is estimated that an abnormal hemoglobin other than hemoglobin E is present in the sample, one or more steps selected from the following are performed: (a) reporting the HbA1c measurement result for the sample as unreportable; (b) reporting the HbA1c measurement result for the sample with an identifier indicating the presence of an abnormal hemoglobin other than hemoglobin E; and (c) calculating HbA1c by including the area of ​​the third peak in the area of ​​the first peak, and reporting the measurement result. [5] The method according to item 4, wherein the abnormal hemoglobin different from hemoglobin E is Hb-Riccarton. [6] The method according to item 1 or 2, wherein in step (4), if the slope is within the predetermined reference threshold range, it is estimated that hemoglobin E is present in the sample.[7] The method according to item 6, wherein, when hemoglobin E is estimated to be present in the sample, HbA1c is calculated by correcting for hemoglobin E using the area of ​​a third peak, and the measurement result is reported. [8] The method according to any one of items 1 to 7, wherein the chromatogram is a chromatogram showing time on the horizontal axis and detector output on the vertical axis, and when the minimum value of the detector output during one measurement in the chromatogram is normalized to 0 and the maximum value to 1000, the predetermined reference threshold range is -30 to 30. [9] The method according to any one of Items 1 to 8, wherein the predetermined reference threshold range is calculated by the following steps: (i) identifying a first peak for HbA1c, a second peak for HbA0, and a third peak for hemoglobin E from a chromatogram showing elution of multiple hemoglobin fractions including at least HbA1c, HbA0, and hemoglobin E, obtained by subjecting a blood-derived sample of a reference specimen containing hemoglobin E to cation exchange liquid chromatography; (ii) identifying a first valley existing between the first peak and the third peak and a second valley existing between the second peak and the third peak, and calculating a reference slope from the minimum point of the first valley and the minimum point of the second valley; and (iii) performing steps (i) to (ii) on multiple reference specimens containing hemoglobin E, and calculating the predetermined reference threshold range from the obtained multiple reference slope values ​​by statistical processing.

[10] A hemoglobin analysis system that executes the method according to any one of items 1 to 9.

[11] The hemoglobin analysis system according to item 10, comprising: a cation exchange liquid chromatography device; and an analysis means for analyzing chromatogram data acquired by the cation exchange liquid chromatography device.

[0012] According to the HbA1c measuring device of the present invention configured as described above, even when a peak is observed between the HbA1c peak and the HbA0 peak and a sample containing abnormal Hb different from HbE (e.g., Hb-Riccarton) is measured, it is possible to appropriately disable reporting of the measurement result or enable reporting of accurate measurement result.

[0013] 1 is a configuration diagram of a measurement device according to an embodiment of the present disclosure. FIG. 2 is a flowchart illustrating an example of an analysis process in the measurement device. FIG. 3 is an example of a chromatogram of a normal sample measured by the measurement device of FIG. 1. FIG. 4 is an example of a chromatogram of an HbE sample measured by the measurement device of FIG. 1. FIG. 5 is an example of a chromatogram of an Hb-Riccarton sample measured by the measurement device of FIG. 1. FIG. 6 is an enlarged view of the chromatogram of the HbE sample of FIG. 4 with an auxiliary line indicating the slope. FIG. 7 is an enlarged view of the chromatogram of the Hb-Riccarton sample of FIG. 5 with an auxiliary line indicating the slope. FIG. 8 is a histogram showing the distribution of the slopes of the valleys forming the peaks of an HbE sample (82 measurements).

[0014] The present invention will be described in more detail below using examples and the like, but the aspects of the present invention are not limited to these. Note that the documents cited in this specification may be incorporated into this specification in their entirety by reference.

[0015] In one aspect, the present invention provides a method for analyzing hemoglobin in a blood-derived sample, comprising: (1) identifying a first peak for HbA1c and a second peak for HbA0 from a chromatogram showing the elution of multiple hemoglobin fractions, including at least HbA1c and HbA0, obtained by subjecting the blood-derived sample to cation exchange liquid chromatography; (2) determining whether or not a third peak exists between the first and second peaks, and if it is determined that the third peak exists and that no peaks other than the third peak exist, the following steps are further carried out; (3) identifying a first valley existing between the first and third peaks and a second valley existing between the second and third peaks, and calculating the slope of a line formed between the first valley and the second valley; and (4) estimating the presence of abnormal hemoglobin in the sample by comparing the slope with a predetermined reference threshold range.

[0016] In one embodiment, the present invention provides a hemoglobin analysis system in which the above-described method is performed. The hemoglobin analysis system provided by the present invention may include an analysis means for analyzing data on a chromatogram obtained by a cation exchange liquid chromatography device, and may be, for example, a computer having a processor (e.g., a CPU or a microcomputer) and having installed therein a control program for executing the above-described method. In another aspect, the present invention may be a computer program for causing the analysis means to execute the above-described method.

[0017] The chromatogram data obtained by the cation exchange liquid chromatography device may be introduced into the analysis means via a network (wired network or wireless network) or a storage medium (e.g., a memory device such as RAM, ROM, or flash memory, a fixed disk device such as a hard disk drive, or a portable storage device such as a flexible disk or optical disk).

[0018] In another aspect, the present invention may comprise a cation exchange liquid chromatography apparatus and an analysis means for analyzing chromatogram data acquired by the cation exchange liquid chromatography apparatus (e.g., FIG. 1). In this case, the computer serving as the analysis means may be integrally and inseparably built into the cation exchange liquid chromatography apparatus, or may be provided as an external device.

[0019] Cation exchange liquid chromatography applicable to the present invention will now be described. The cation exchange column is prepared using a packing material in which cation exchange groups have been introduced into non-porous cross-linked polymer particles. The synthesis method for the non-porous cross-linked polymer particles is not limited, and known methods such as suspension polymerization, emulsion polymerization, seed polymerization, and precipitation polymerization can be used. Furthermore, the present invention is not limited to non-porous cross-linked polymer particles; porous cross-linked polymers can also be used. The monomers and cross-linking agents used in the synthesis are not particularly limited, but hydrophilic methacrylic acid and acrylic esters are preferred. Examples of monomers include hydroxyethyl methacrylate, hydroxyethyl acrylate, hydroxypropyl acrylate, glycerin methacrylate, polyethylene glycol methacrylate, and polyethylene glycol acrylate. Examples of cross-linking agents include ethylene glycol dimethacrylate, diethylene glycol dimethacrylate, triethylene glycol dimethacrylate, and glycerin dimethacrylate.

[0020] When non-porous cross-linked polymer particles are used, there are no particular limitations on the method for introducing cation exchange groups onto the surface, and any known introduction method can be used. Examples of the cation exchange groups to be introduced include sulfopropyl groups, sulfoethyl groups, and carboxymethyl groups. Similar examples can be used when porous cross-linked polymers are used.

[0021] The eluent used in the cation exchange liquid chromatography applicable to the present invention is not particularly limited, and may be a buffer solution containing an organic acid such as succinic acid or citric acid and its salt, a buffer solution containing an inorganic acid such as phosphoric acid and its salt, or a mixture of organic and inorganic acids. If necessary, other salts such as sodium chloride, sodium nitrate, and sodium sulfate may be added to the buffer solution.

[0022] In the examples, an automatic glycohemoglobin analyzer HLC-723GR01 (standard short mode) (manufactured by Tosoh Corporation) was used as a cation exchange liquid chromatography device to obtain a chromatogram showing the elution of hemoglobin fractions, but this is not limiting. This device is a liquid chromatography device based on the principle of cation exchange chromatography. The main system configuration of this device will be described with reference to Figure 1.

[0023] The analytical column (19) used was TSKgel GR01 (standard short mode) (manufactured by Tosoh Corporation), and the eluents used were GR01 eluent 1 (10), GR01 eluent 2 (11), and GR01 eluent 3 (12). Under these measurement conditions, a measurement time of 30 seconds per sample was possible.

[0024] The eluents (10, 11, 12) are delivered by a delivery pump 14 and introduced into an analytical column 19 together with a measurement sample injected by an autosampler 18. The eluents (10, 11, 12) are passed through a degasser 13 as needed, and different eluent mixture ratios are created by switching solenoid valves (15, 16, 17). The analytical column separates various components based on differences in salt concentration, etc., resulting from the mixture ratios, and the fractions are sequentially eluted. The sequentially eluted fractions are introduced into a detector 20, and the output values ​​are continuously acquired.

[0025] The degassing device 13, solenoid valves (15, 16, 17), liquid pump 14, autosampler 18, column oven 21, and detector 20 are controlled by a control / processing unit 22, such as a microcomputer or CPU, based on a control program and measurement conditions pre-stored in a storage unit 23. The detector signal obtained by the detector 20 is converted by the control / processing unit 22 into plot data consisting of, for example, time and detector signal. A chromatogram is then created based on this plot data. This chromatogram is then waveform-processed, and quantitative calculation of HbA1c is performed based on pre-stored calibration data, etc. The obtained quantitative calculation results, chromatogram, etc. can be displayed on a display unit 24, and this data can also be stored in a data storage unit 25.

[0026] In one embodiment of the present invention, a chromatogram is obtained from plot data in which the horizontal axis represents time (retention time) [t] and the vertical axis represents detector output (signal output) such as absorbance [A]. Alternatively, the horizontal axis may represent elution volume. The vertical axis may also represent a value converted from the detector signal. For example, corrections such as noise reduction, smoothing, drift reduction, or baseline correction may be performed. Normalization is a method for displaying chromatograms that eliminates the influence of measurement conditions, environmental conditions, and the like for comparison.

[0027] In one embodiment of the present invention, normalization may be performed by setting the minimum value of the detector output in the plot data of one measurement to 0, the maximum value of the detector output to 1000, and multiplying the other points by a constant so that the ratios are equivalent. This normalization condition is intended to relatively evaluate a specific peak height in different measurements or samples, and can be based on an arbitrary time point or an arbitrary peak top, or may be performed on the horizontal axis.

[0028] Generally, HbA1c is calculated by the ratio of the HbA1c peak area to the total hemoglobin area (total area) in a chromatogram obtained by fractionating a sample containing hemoglobin. To correct for deviations in the measurement method or conditions relative to the true value or reference value, calibration is generally performed based on the measurement results of a known sample. Furthermore, in order to eliminate abnormal hemoglobin or modified hemoglobin that affect the HbA1c measurement results, there are also methods for removing the peak area of ​​the influencing peak from the total area, or for correcting the results before and after calibration. For example, when hemoglobin E is estimated to be present in a sample according to the present invention, as shown in Patent Document 1 (JP 2012-215470 A), in measuring HbA1c containing abnormal hemoglobin E, a peak appearing between the peak of non-glycated hemoglobin A and the peak of sA1c is identified as the peak of abnormal hemoglobin E, the area of ​​the peak for abnormal hemoglobin E is calculated, and the calculation result is used to correct the peak area of ​​HbA1c or the peak area of ​​total hemoglobin, thereby obtaining a measurement result of HbA1c.

[0029] 2 is an example of a flowchart illustrating the method of one embodiment of the present invention. An example of an abnormal hemoglobin that can be estimated using this flowchart is Hb-Riccarton, which is an abnormal Hb different from HbE and has a peak (corresponding to the third peak) between the HbA1c peak (corresponding to the first peak) and the HbA0 peak (corresponding to the second peak).

[0030] Figure 3 shows an example of a chromatogram obtained by measuring HbA1c in a typical sample. An HbA1c peak (corresponding to the first peak) and an HbA0 peak (corresponding to the second peak) are observed, but no peak is observed between the HbA1c and HbA0 peaks.

[0031] FIG. 4 shows an example of a chromatogram obtained by measuring HbA1c in a sample containing hemoglobin E, and FIG. 5 shows an example of a chromatogram obtained by measuring HbA1c in a sample containing Hb-Riccarton. It can be seen that both hemoglobin E and Hb-Riccarton have a peak (corresponding to the third peak) between HbA1c and HbA0, and no other abnormal peaks are present. Although the details of hemoglobin E and Hb-Riccarton are unknown, various studies have shown that they have similar elution positions regardless of the cation exchange group or eluent conditions. It has been found that separating the two requires an extended measurement time or worsening of other peak elution conditions. Furthermore, comparing the two solely based on the difference in elution time is prone to misidentification due to differences between instruments, between measurement days, and between measurement conditions.

[0032] A flowchart illustrating one aspect of the present invention will be described. In a chromatogram obtained by analyzing a target sample, first, a determination is made as to whether there is another peak (third peak) between the HbA1c peak (first peak) and the HbA0 peak (second peak), and whether there are any other abnormal peaks (S1). If no peak is obtained between the HbA1c and HbA0 peaks, it is determined that there is no abnormal Hb (e.g., Hb-Riccarton) present, in which hemoglobin E or an abnormal Hb is present between the HbA1c and HbA0 peaks. These samples may contain, in addition to standard samples, abnormal Hb that are present at peaks other than those between the HbA1c and HbA0 peaks. However, in this embodiment, the processing of abnormal Hb samples that are present at peaks other than those between the HbA1c and HbA0 peaks will be omitted, and these samples will be referred to as standard samples (*) (Figure 2). If a peak (third peak) is obtained between the HbA1c and HbA0 peaks, the slope of the valley at that peak is calculated (S2). The slope can be determined by calculating the rate of change between two different points between the HbA1c peak (first peak) and the HbA0 peak (second peak), or by fitting the peaks of the chromatogram to a continuous function and determining the slope of the tangent to any point. From the perspective of computational processing volume, it is desirable to calculate the slope of the valley (minimum) formed on either side of the peak top of the peak. For example, if the valley between the first and third peaks is identified as the "first valley" and the valley between the second and third peaks is identified as the "second valley," and the plot data of the minimum point with early elution (i.e., the "minimum point of the first valley") is (t1, A1) and the plot data of the minimum point with slow elution (i.e., the "minimum point of the second valley") is (t2, A2), the slope representing the rate of change can be exemplified as (A2-A1) / (t2-t1).

[0033] Next, the slope value is compared with a predetermined reference threshold range previously set and stored in the HbA1c measuring device (S3). If this comparison reveals that the slope deviates from the predetermined reference threshold range, it can be assumed that an abnormal Hb other than HbE (e.g., Hb-Riccarton) is present. On the other hand, if the slope falls within the predetermined reference threshold range, it can be assumed that HbE is present. This predetermined reference threshold range may be set at the time of manufacturing and selling the system of the present invention, or it can be newly set or changed by the user. Furthermore, when measuring known HbE samples, the values ​​can be stored, and the values ​​can be set or updated using the mean, median, standard deviation, variance, or statistical processing based on these values. For example, in one embodiment, the predetermined reference threshold range may be calculated by the following steps: (i) identifying a first peak for HbA1c, a second peak for HbA0, and a third peak for hemoglobin E from a chromatogram showing the elution of multiple hemoglobin fractions including at least HbA1c, HbA0, and hemoglobin E, obtained by subjecting a blood-derived sample of a reference specimen containing hemoglobin E to cation exchange liquid chromatography; (ii) identifying a first valley existing between the first peak and the third peak and a second valley existing between the second peak and the third peak, and calculating a reference slope from the minimum point of the first valley and the minimum point of the second valley; and (iii) performing steps (i) to (ii) on multiple reference specimens containing hemoglobin E, and calculating the predetermined reference threshold range from the obtained multiple reference slope values ​​by statistical processing.

[0034] If the present invention predicts the presence of abnormal Hb different from HbE (Hb-Riccarton, etc.), calculation of HbA1c in the presence of HbE (for example, the method described in Patent Document 1) may not be performed, or the HbA1c measurement results may be reported as unreportable.

[0035] Alternatively, an identifier such as a message or flag may be added to indicate that the measurement result suggests the presence of an abnormal hemoglobin other than HbE (for example, Hb-Riccarton).

[0036] In another aspect, when it is estimated that an abnormal Hb different from HbE (such as Hb-Riccarton) is present, the same HbA1c calculation as in the case of the presence of HbE is not performed, but an HbA1c calculation tailored to the case of the presence of an abnormal Hb different from HbE (such as Hb-Riccarton) is performed, and the HbA1c can be reported. As such a method, for example, the area of ​​the third peak may be included in the area of ​​the first peak to calculate HbA1c, and the measurement result may be reported.

[0037] Abnormal hemoglobin Hb-Riccarton is hemoglobin having an α-globin chain mutant in which the 51st amino acid, glycine (Gly), of the α-globin chain, which is one of the subunits that make up hemoglobin, is mutated to serine (Ser) (see, for example, Non-Patent Document 1).

[0038] The present invention will be described in more detail below using examples and comparative examples, but the present invention is not limited to these examples.

[0039] Example 1 HbE samples and Hb-Riccarton were obtained from Analytical Control Systems, The European Reference Laboratory for Glycohemoglobin, Eurofins. Genetic analysis of each sample was performed at Fukuyama Clinical Laboratory Center.

[0040] FIG. 6 is an enlarged view of the peak present between the HbA1c peak and the HbA0 peak in an HbE sample, and the dotted lines are auxiliary lines showing the slopes of the two valleys that form the peak relative to the chromatogram coordinate points.

[0041] At this time, the deviation of the time (horizontal axis) between the two points was Δt=0.0354, the deviation of the detector output (vertical axis) was ΔA=0.03, and the slope was ΔA / Δt=0.85.

[0042] FIG. 7 is an enlarged view of the peak present between the HbA1c peak and the HbA0 peak in an HbE sample, and the dotted lines are auxiliary lines showing the slopes of the two valleys that form the peak relative to the chromatogram coordinate points.

[0043] At this time, the deviation in time (horizontal axis) between the two points was Δt=0.0417, the deviation in detector output (vertical axis) was ΔA=-3.816, and the slope was ΔA / Δt=-91.5.

[0044] Figure 8 shows a histogram of the slope of the valley that forms the peak between the HbA1c and A0 peaks, obtained by measuring multiple HbE samples using multiple devices (82 measurements). Mean: -4.2, standard deviation: 9.0, variance: 81.3, median: -5.0, maximum: 21.8, minimum: -25.9. Based on these conditions and the results of the maximum and minimum values, the threshold range was set to between -30 and 30. The reference threshold range can also be determined statistically using other methods, such as the mean ± standard deviation × constant, or the 95% range assuming a normal distribution.

[0045] Two new Hb-Riccarton-containing specimens were measured, and the slopes of the valleys forming the peaks between the HbA1c and A0 peaks were -109 and -94, respectively, which were below the preset threshold of -30, and therefore could be correctly detected as peaks distinct from HbE. Furthermore, when the Hb-Riccarton-containing specimens (two specimens) were measured using affinity chromatography (HLC-723G8 affinity mode), which is thought to be less susceptible to the influence of abnormal hemoglobin, the results obtained were 5.6% and 5.9%.

[0046] When HbA1c was measured using the same method as for HbE in the same specimen, the results were 5.3% and 5.6%, respectively.

[0047] Next, when HbA1c was measured by including the peak area between the HbA1c and A0 peaks in the HbA1c peak area, the results were 5.6% and 6.0%, respectively, which were close to the reference values ​​obtained by affinity chromatography.

[0048] Here, the method for calculating HbE is a method in which the peak area due to abnormal HbE is subtracted from the peak area of ​​total hemoglobin to obtain a corrected value of the peak area of ​​total hemoglobin (corrected area), and the peak area of ​​HbA1c is divided by this corrected area to calculate the proportion (%) of HbA1c.

[0049] (Example 2) This is carried out in an apparatus in which the reference threshold value is not set in the initial state.

[0050] When a sample in which the presence of HbE is confirmed or highly likely to be present is measured, that information is registered in the device. The device also stores the slope of the valley forming the peak between the HbA1c and HbA0 peaks obtained from the measurement results. The device also updates the reference threshold from the slope information accumulated up to that point and performs judgments on unknown samples based on that reference threshold.

[0051] REFERENCE SIGNS LIST 1 Analysis means 2 Cation exchange liquid chromatography device 10 First eluent 11 Second eluent 12 Third eluent 13 Degasser 14 Liquid feed pump 15, 16, 17 Solenoid valve 18 Autosampler 19 Analytical column 20 Detector 21 Column oven 22 Control / processing unit 23 Storage unit 24 Display unit (input unit) 25 Data storage unit

Claims

1. A method for analyzing hemoglobin in a blood-derived sample, comprising the steps of: (1) identifying a first peak for HbA1c and a second peak for HbA0 from a chromatogram showing the elution of a plurality of hemoglobin fractions including at least HbA1c and HbA0, obtained by subjecting a blood-derived sample to cation exchange liquid chromatography; (2) determining whether or not a third peak exists between the first and second peaks, and if it is determined that the third peak exists and that no peak other than the third peak exists, the following steps are carried out; (3) identifying a first valley existing between the first and third peaks and a second valley existing between the second and third peaks, and calculating the slope of a straight line formed between the first valley and the second valley; and (4) estimating the presence of abnormal hemoglobin in the sample by comparing the slope with a predetermined reference threshold range.

2. The method according to claim 1, wherein in step (3), the slope is calculated from a minimum point of the first valley and a minimum point of the second valley.

3. The method according to claim 1, wherein in step (4), if the slope deviates from the predetermined reference threshold range, it is presumed that an abnormal hemoglobin other than hemoglobin E is present in the sample.

4. The method according to claim 3, wherein, when it is estimated that abnormal hemoglobin other than hemoglobin E is present in the sample, one or more steps selected from the following are carried out: (a) responding that the measurement result of HbA1c for the sample cannot be reported; (b) responding with the measurement result of HbA1c for the sample by assigning an identifier indicating the presence of abnormal hemoglobin other than hemoglobin E; and (c) calculating HbA1c by including the area of ​​the third peak in the area of ​​the first peak, and responding with the measurement result.

5. The method according to claim 4, wherein the abnormal hemoglobin different from hemoglobin E is Hb-Riccarton.

6. The method of claim 1, wherein in step (4), if the slope falls within the predetermined reference threshold range, hemoglobin E is presumed to be present in the sample.

7. The method according to claim 6, wherein, when hemoglobin E is estimated to be present in the sample, HbA1c is calculated by correcting for hemoglobin E using the area of ​​the third peak, and the measurement result is returned.

8. The method according to claim 1, wherein the chromatogram has time on the horizontal axis and detector output on the vertical axis, and when the minimum value of the detector output during one measurement in the chromatogram is normalized to 0 and the maximum value to 1000, the predetermined reference threshold range is from -30 to 30.

9. The method of claim 1, wherein the predetermined reference threshold range is calculated by the following steps: (i) identifying a first peak for HbA1c, a second peak for HbA0, and a third peak for hemoglobin E from a chromatogram showing elution of a plurality of hemoglobin fractions including at least HbA1c, HbA0, and hemoglobin E, the chromatogram being obtained by subjecting a blood-derived sample of a reference specimen containing hemoglobin E to cation exchange liquid chromatography; (ii) identifying a first valley existing between the first peak and the third peak and a second valley existing between the second peak and the third peak, and calculating a reference slope from the minimum point of the first valley and the minimum point of the second valley; and (iii) performing (i) to (ii) on a reference specimen containing a plurality of hemoglobin E, and calculating the predetermined reference threshold range from the obtained plurality of reference slope values ​​by statistical processing.

10. A hemoglobin analysis system, in which the method of claim 1 is performed.

11. The hemoglobin analysis system according to claim 10, comprising: a cation exchange liquid chromatography device; and an analysis means for analyzing chromatogram data obtained by said cation exchange liquid chromatography device.

Citation Information

Patent Citations

  • Method and device for measuring glycosylated hemoglobin

    JP2012215470A

  • Abnormal hemoglobin detection method

    JP2004061461A

  • Measuring method, measuring apparatus and eluent

    JP2016027326A

  • QUANTITATIVE METHOD OF STABLE TYPE GLYCOSYLATED HEMOGLOBIN A1c

    JP2016183871A

  • Hemoglobin analyzer

    JP2022090737A